West Midlands Atrial Fibrillation Advance Programme

West Midlands Atrial Fibrillation Advance Programme

Expression of Interest to participate in use of AliveCor Kardia device to detect Atrial Fibrillation

WestMidlandsAcademic Health Science Network have joined forces to implement the Atrial Fibrillation Advance Programme to work with CCGs in the West Midlands to improve the diagnosis and management of atrial fibrillation.As part of this programme we are planning to provide organisations who are interested with the AliveCorKardia device which will support you in the detection of people with atrial fibrillation in your population.

If your CCG/GP practice would like to participate, please complete the expression of interest form by Friday 2nd March through uploading this completed form to the campaign on Meridian health innovation exchange (expressions-of-interest/end). Meridian is free to register to and the document can be dragged into a ‘Submit Innovation’ form within the campaign.

Organisation contact details
Name
Name of organisation
Addressfor delivery of devices
Lead contact name
Lead contact role
Email address
Direct Dial Telephone Number
Clinical Champion and Upskilling in AF if applicable
What is the name and email address for your Clinical Champion who will take the lead for implementing the AliveCor Kardia device within your GP practice? / Name:
Email:
Has your Clinical Champion attended an upskilling workshop or course on atrial fibrillation?
Number of AliveCor Kardia devices
Do you currently have any AliveCor devices already? / YES / NO. If YES, please state how many?
How many AliveCor devices are you bidding for – based on the number of people you are planning on seeing and where will these be distributed?
Note: please note we may not be able to provide all these from our allocation.
Commitment to use of devices to improve diagnosis of AF
I would like to participate in the implementation of the AliveCor Kardia device to improve the detection of atrial fibrillation / YES / NO
Who will be using the devices.
Confirm that the training/guidance will be given to the users
Link to the guidance document…..
Availability within the organisation of phones or tablets to support use the AliveCor device
To use the AliveCor Kardia device it has to be attached to an android phone or tablet or iPhone or iPad tablet. A list of compatible Apple & Android phones and tablets is available via this link
How does your organisation intend to use the devices?
Plan to use their personal phones or tablets / YES / NO
Will be able to use organisation phones or tablets / YES / NO
Plans for use of AliveCor Kardia devices
The plans to target use of the AliveCor Kardia device in the following ways:
Opportunistic screening during routine consultations / YES / NO
During Flu Clinics to be held this year (2017-18) / YES / NO
Hypertension Annual Review Clinics / YES / NO
Obstructive Sleep Apnoea patients / YES / NO
Heart Failure patients / YES / NO
Annual Review of patients with long term conditions including Stroke, CVD, IHD, PAD, COPD, Diabetes / YES / NO
BMI >40 / YES / NO
Other please state:
Please describe how you plan to use the devices. In what setting, how many people, what’s your target population
Provide your response here…
Do you plan to measure the usage of AliveCor and if so how will this be measured and recorded?
Provide your response here…
Describe how you will manage people who are found to have an abnormal reading
Provide your response here…
Evidence summary: 1) Age is the biggest non-modifiable risk factor for AF (AF prevalence roughly doubles with each successive decade of life after 65);
2) Hypertension is the commonest modifiable risk factor for AF in a western population, 3) Obstructive sleep apnoea patients have a 7 fold lifetime increase risk of AF
AF Toolkit
We are developing resources to support GP practices in implementing the AliveCor device including protocol and will make these available at the events in March
Agreement to implement AliveCor Kardia device and provide information on outcomes
The organisation agrees to implement the AliveCor Kardia device as outlined above
The organisation agrees to support evaluation of the outcomes of using the AliveCor devices by providing the following information to West Midlands Academic Health Science Network:(practices can easily get this information by running GraspAF report)

Number of AF patients: 1) diagnosed with atrial fibrillation; 2) AF patients at high risk of a stroke; 3)AF patients at high risk of stroke on anticoagulation treatment
Quarterly information as follows: baseline data as at end of March 2018 followed by quarterly at endJune 2018, September 2018, December 2018, March 2019

Signature: / Name:
Title: / Date: